Show simple item record

dc.contributor.authorRobles-Zurita, J
dc.contributor.authorBoyd, KA
dc.contributor.authorBriggs, AH
dc.contributor.authorIveson, T
dc.contributor.authorKerr, RS
dc.contributor.authorSaunders, MP
dc.contributor.authorCassidy, J
dc.contributor.authorHollander, NH
dc.contributor.authorTabernero, J
dc.contributor.authorSegelov, E
dc.contributor.authorGlimelius, B
dc.contributor.authorHarkin, A
dc.contributor.authorAllan, K
dc.contributor.authorMcQueen, J
dc.contributor.authorPearson, S
dc.contributor.authorWaterston, A
dc.contributor.authorMedley, L
dc.contributor.authorWilson, C
dc.contributor.authorEllis, R
dc.contributor.authorEssapen, S
dc.contributor.authorDhadda, AS
dc.contributor.authorHughes, R
dc.contributor.authorFalk, S
dc.contributor.authorRaouf, S
dc.contributor.authorRees, C
dc.contributor.authorOlesen, RK
dc.contributor.authorPropper, D
dc.contributor.authorBridgewater, J
dc.contributor.authorAzzabi, A
dc.contributor.authorFarrugia, D
dc.contributor.authorWebb, A
dc.contributor.authorCunningham, D
dc.contributor.authorHickish, T
dc.contributor.authorWeaver, A
dc.contributor.authorGollins, S
dc.contributor.authorWasan, HS
dc.contributor.authorPaul, J
dc.date.accessioned2019-02-20T07:50:45Z
dc.date.issued2018-11-13
dc.identifier.citationBritish journal of cancer, 2018, 119 (11), pp. 1332 - 1338
dc.identifier.issn0007-0920
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/3065
dc.identifier.eissn1532-1827
dc.identifier.doi10.1038/s41416-018-0319-z
dc.description.abstractBackground The Short Course Oncology Therapy (SCOT) study is an international, multicentre, non-inferiority randomised controlled trial assessing the efficacy, toxicity, and cost-effectiveness of 3 months (3 M) versus the usually given 6 months (6 M) of adjuvant chemotherapy in colorectal cancer.Methods In total, 6088 patients with fully resected high-risk stage II or stage III colorectal cancer were randomised and followed up for 3-8 years. The within-trial cost-effectiveness analysis from a UK health-care perspective is presented using the resource use data, quality of life (EQ-5D-3L), time on treatment (ToT), disease-free survival after treatment (DFS) and overall survival (OS) data. Quality-adjusted partitioned survival analysis and Kaplan-Meier Sample Average Estimator estimated QALYs and costs. Probabilistic sensitivity and subgroup analysis was undertaken.Results The 3 M arm is less costly (-£4881; 95% CI: -£6269; -£3492) and entails (non-significant) QALY gains (0.08; 95% CI: -0.086; 0.230) due to a better significant quality of life. The net monetary benefit was significantly higher in 3 M under a wide range of monetary values of a QALY. The subgroup analysis found similar results for patients in the CAPOX regimen. However, for the FOLFOX regimen, 3 M had lower QALYs than 6 M (not statistically significant).Conclusions Overall, 3 M dominates 6 M with no significant detrimental impact on QALYs. The results provide the economic case that a 3 M treatment strategy should be considered a new standard of care.
dc.formatPrint-Electronic
dc.format.extent1332 - 1338
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.subjectHumans
dc.subjectColorectal Neoplasms
dc.subjectAntineoplastic Combined Chemotherapy Protocols
dc.subjectChemotherapy, Adjuvant
dc.subjectSurvival Analysis
dc.subjectQuality-Adjusted Life Years
dc.subjectQuality of Life
dc.subjectCost-Benefit Analysis
dc.subjectOxaliplatin
dc.titleSCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer.
dc.typeJournal Article
dcterms.dateAccepted2018-10-09
rioxxterms.versionofrecord10.1038/s41416-018-0319-z
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2018-11-13
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfBritish journal of cancer
pubs.issue11
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham)/Medicine (RMH Smith Cunningham) (hon.)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham)/Medicine (RMH Smith Cunningham) (hon.)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublished
pubs.volume119
pubs.embargo.termsNot known
icr.researchteamMedicine (RMH Smith Cunningham)en_US
dc.contributor.icrauthorCunningham, Daviden


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0